With the recent emergence of a novel coronavirus, and the subsequent pandemic, research began on the first vaccine development efforts leveraging an mRNA vaccine platform. This new platform offered the advantages of both efficiency and flexibility in immunogen design, which proved critical for developing a therapeutic that could provide protective immunity in the face of the SARS COVID-19 outbreak, for which much of the world was unprepared. As a leading provider of assay development and testing services for clinical development of vaccines and antivirals, Eurofins Viracor has supported multiple clinical trials for vaccine manufacturers. So, when Moderna was gearing up for clinical studies of their mRNA-1273 COVID-19 vaccine candidate they reached out to Viracor to provide quantitative polymerase chain reaction (qPCR) assay development, validation, and testing.
Check out this case study to learn about the RT-qPCR and NGS assay development and testing services Viracor provided to support this critical clinical trial.